Veracyte Announces Novel Afirma-Based Findings that Advance Molecular Understanding of Thyroid Cancer to Be Presented at the 2023 ATA Annual Meeting

On September 21, 2023 Veracyte, Inc. (Nasdaq: VCYT) reported that three posters showcasing new data from the company’s Afirma Genomic Sequencing Classifier (GSC) will be presented at the 2023 American Thyroid Association (ATA) Annual Meeting being held in Washington, DC from September 27 to October 1 (Press release, Veracyte, SEP 21, 2023, View Source [SID1234635317]). Together, these abstracts offer novel insights into the molecular underpinnings of thyroid nodules and tumors based on whole-transcriptome RNA sequencing data from thyroid nodules analyzed with the Afirma GSC.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"As we enter a new era in the personalized diagnosis and management of thyroid nodules and cancer, it is more important than ever to advance the science around this cancer so we can ultimately characterize each patient’s individual molecular profile," said Joshua Klopper, MD, Veracyte’s medical director for Endocrinology. "The abstracts to be presented by our clinical research colleagues at the ATA meeting show that the Afirma GSC platform can be used to glean new insights about thyroid nodules and thyroid cancer preoperatively. We believe that Afirma-based whole-transcriptome analysis will help drive cancer research and unlock findings that may ultimately be used in clinical care."

The following late-breaking posters will be presented at the 2023 ATA Annual Meeting (all times ET):

Title: Leveraging RNA Sequencing for Pre-Operative Immunophenotyping of BRAFV600E+ Thyroid Nodules
Presenter: Jarod Olay, M.S., UCLA David Geffen School of Medicine
Poster #: 502
Date/Time: September 28; 10:00 a.m. – 10:30 a.m. and 11:35 a.m. – 12:45 p.m.
Title: Molecular Assessment of Isthmus Thyroid Carcinomas

Presenter: Sina Jasim, M.D., Washington University in St. Louis
Poster #: 501
Date/Time: September 28; 10:00 a.m. – 10:30 a.m. and 11:35 a.m. – 12:45 p.m.
Title: Sodium Iodide Symporter (NIS) Expression in Cytologically Indeterminate and Malignant Thyroid Nodules

Presenter: Prasana Santhanam, M.B.B.S., M.D., The Johns Hopkins University School of Medicine
Poster #: 515
Date/Time: September 28; 10:00 a.m. – 10:30 a.m. and 11:35 a.m. – 12:45 p.m.

These abstracts will later be published as an online supplement to Thyroid, the official journal of the ATA.